Business Description
Fuan Pharmaceutical (Group) Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE1000011G4
Share Class Description:
SZSE:300194: Class ACompare
Compare
Traded in other countries / regions
300194.China IPO Date
2011-03-22Description
Fuan Pharmaceutical (Group) Co Ltd is mainly engaged in the production and sales of bulk drugs and preparations. The company mainly deals with anti-infective, anti-tumor, mental nervous system, cardiovascular and cerebrovascular, digestive system, endocrine and metabolic, bone and muscle systems. Its products include penicillin and cephalosporins.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.36 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | 1.86 | |||||
| Interest Coverage | 11.72 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.05 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.1 | |||||
| 3-Year EBITDA Growth Rate | 7.4 | |||||
| 3-Year EPS without NRI Growth Rate | -60.3 | |||||
| 3-Year Book Growth Rate | 0.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 213.45 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.09 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.99 | |||||
| 9-Day RSI | 35.04 | |||||
| 14-Day RSI | 38.95 | |||||
| 6-1 Month Momentum % | 32.89 | |||||
| 12-1 Month Momentum % | 16.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.66 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.74 | |||||
| Days Inventory | 206.45 | |||||
| Days Sales Outstanding | 37.2 | |||||
| Days Payable | 116.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.1 | |||||
| Dividend Payout Ratio | 0.21 | |||||
| Forward Dividend Yield % | 1.1 | |||||
| 5-Year Yield-on-Cost % | 1.1 | |||||
| Shareholder Yield % | 4.85 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.33 | |||||
| Operating Margin % | 11.48 | |||||
| Net Margin % | 10.59 | |||||
| FCF Margin % | 8.24 | |||||
| ROE % | 6.61 | |||||
| ROA % | 4.66 | |||||
| ROIC % | 5.37 | |||||
| ROC (Joel Greenblatt) % | 19.16 | |||||
| ROCE % | 7.97 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.04 | |||||
| Forward PE Ratio | 12.13 | |||||
| PE Ratio without NRI | 18.97 | |||||
| Shiller PE Ratio | 41.91 | |||||
| Price-to-Owner-Earnings | 461 | |||||
| PS Ratio | 2.16 | |||||
| PB Ratio | 1.25 | |||||
| Price-to-Tangible-Book | 1.53 | |||||
| Price-to-Free-Cash-Flow | 26.02 | |||||
| Price-to-Operating-Cash-Flow | 12.27 | |||||
| EV-to-EBIT | 13.43 | |||||
| EV-to-EBITDA | 13.43 | |||||
| EV-to-Revenue | 1.93 | |||||
| EV-to-FCF | 23.67 | |||||
| Price-to-Projected-FCF | 1.61 | |||||
| Price-to-Median-PS-Value | 0.9 | |||||
| Price-to-Graham-Number | 1.14 | |||||
| Price-to-Net-Current-Asset-Value | 10.48 | |||||
| Earnings Yield (Greenblatt) % | 7.45 | |||||
| FCF Yield % | 4 | |||||
| Forward Rate of Return (Yacktman) % | 21.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fuan Pharmaceutical (Group) Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 2,660.049 | ||
| EPS (TTM) (Â¥) | 0.23 | ||
| Beta | 1.09 | ||
| Volatility % | 34.42 | ||
| 14-Day RSI | 38.95 | ||
| 14-Day ATR (Â¥) | 0.144804 | ||
| 20-Day SMA (Â¥) | 4.894 | ||
| 12-1 Month Momentum % | 16.12 | ||
| 52-Week Range (Â¥) | 2.92 - 5.68 | ||
| Shares Outstanding (Mil) | 1,189.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fuan Pharmaceutical (Group) Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fuan Pharmaceutical (Group) Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fuan Pharmaceutical (Group) Co Ltd Frequently Asked Questions
What is Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194)'s stock price today?
The current price of SZSE:300194 is ¥4.61. The 52 week high of SZSE:300194 is ¥5.68 and 52 week low is ¥2.92.
When is next earnings date of Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194)?
The next earnings date of Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194) is .
Does Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194) pay dividends? If so, how much?
The Dividend Yield %  of Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194) is 1.1% (As of Today), Highest Dividend Payout Ratio of Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194) was 5. The lowest was 0.15. And the median was 0.39. The  Forward Dividend Yield % of Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194) is 1.1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers